Skip to main content
Contact Us
Subscribe
E-Edition
76°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Archives
Best of 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Latest News about ATAI Life Sciences
Recent news which mentions ATAI Life Sciences
Atai Q3 Report: Strong Cash Position, Clinical Pipeline Growth
November 13, 2024
Tickers
ATAI
DMT
MDMA
NEWS
Tags
Srinivas Rao
Market News
ATAI
From
Benzinga
Psychedelics 2.0: Companies Explore Safer, More Targeted Therapies
October 04, 2024
Tickers
ATAI
ENVB
NEWS
Tags
Psychedelics 2/0
Psychedelic Research
Srinivas Rao
From
Benzinga
MDMA Therapy For PTSD Faces FDA Delay: Are There Other Ways Forward?
September 12, 2024
Tickers
ATAI
CMPS
DMT
MBIO
Tags
Numinus Wellness
Psychedelics
Psychedelic Assisted Therapies
From
Benzinga
Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration
September 05, 2024
Tickers
ABBV
ATAI
CMPS
COMP
Tags
market projections
Psychedelics
Johnson & Johnson
From
Benzinga
Atai's DMT Depression Drug Shows Promise, Prepares For Phase II Trial And Future Collaboration With Pharma Giant
August 14, 2024
Tickers
ATAI
Tags
VLS/01
Psychedelics
Benzinga
From
Benzinga
atai Life Sciences advances VLS-01 for treatment-resistant depression
March 12, 2024
Tags
XNAS:ATAI
atai Life Sciences
From
TheNewswire.com - RSS (Media)
atai's Phase 1 Synthetic DMT-Based Drug Clinical Trial Begins Patient Dosing
October 05, 2022
Tickers
ATAI
Tags
Benzinga
Psychedelics
treatment/resistant depression
From
Benzinga
Atai Life Sciences: Capital Raise, Share Options, Cathy Wood And More On Biotech Psychedelics Leader
July 07, 2022
Tickers
ATAI
Tags
ARK Genomic Revolution EFT
Benzinga
Psychedelics
From
Benzinga
ATAI Life Sciences Present A "New Recipe For Success" At The Psychedelic Capital Conference
April 29, 2022
Tickers
ATAI
Tags
Market News
ATAI
Markets
From
Benzinga
atai Life Sciences Announces Fourth Quarter and Full Year 2021 Financial Results
March 30, 2022
Tickers
ATAI
CMPS
IGXT
Tags
Markets
Cannabis
CMPS
From
Benzinga
Are Psychedelics Starting to Emerge as Legitimate Therapies?
January 19, 2022
Tickers
DMT
MDMA
Tags
Atai Life Sciences
MindMed (MMED/NEO MMEDF)
MDMA
From
Stock Gumshoe
National Institute on Drug Abuse Will Test Ibogaine For Addiction Treatment As Drug Deaths Crest 100,000
December 08, 2021
Tickers
ATAI
NVMDF
Tags
Market News
Cannabis
Markets
From
Benzinga
New York's Horizons Psychedelic Conference Highlights Big Donations In The Growing Industry
December 07, 2021
Tickers
ATAI
SPCE
TSLA
Tags
SPCE
Startups
Joe Green
From
Benzinga
Peter Thiel-Backed Psychedelic Start-Up, ATAI Life Sciences, Increases Stake In Compass Pathways
November 29, 2021
Tickers
ATAI
CMPS
Tags
Government
Benzinga
Compass Pathways
From
Benzinga
This Psychedelics Stock Was Up More Than 20% Last Week, Outperforming Tesla, Nvidia and GameStop
November 02, 2021
Tickers
ATAI
GME
NVDA
TSLA
Tags
Small Business
General
Binary Options
From
Benzinga
Journey Clinical raises $3M to allow psychotherapists to prescribe psychedelics
September 17, 2021
Tickers
TC
Tags
Columbia University
ela madej
depression
From
TechCrunch
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.